Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome (ARDS-MSC-205)

NCT04447833 PHASE1 ACTIVE_NOT_RECRUITING

This is an open label, dose escalating safety study of the advanced therapy investigational medicinal product (ATIMP) KI-MSC-PL-205, where patients diagnosed with SARS-CoV-2-induced severe acute respiratory distress syndrome (ARDS), according to the Berlin Definition, and who are on respirator/ventilator (used synonymously in this protocol) support due to respiratory insufficiency with or without concomitant circulatory problems, will be included and treated with a single dose of KI-MSC-PL-205.

Details

Lead sponsor	Uppsala University
Phase	PHASE1
Status	ACTIVE_NOT_RECRUITING
Enrolment	7
Start date	Wed Jun 17 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Mar 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• ARDS, Human
• COVID

Interventions

• Mesenchymal Stromal Stem Cells - KI-MSC-PL-205

Countries

Sweden